Does ITI Actually Work in Hemophilia B – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Shaoyu Yin et al, adding:
“Immune tolerance induction (ITI) in hemophilia B: does it actually work?
This systematic review makes one thing clear: ITI in hemophilia B is unpredictable and risky.
What the data show:
Across 125 patients:
- Success rates vary wildly (from 12.8 pecent to 100 percent)
- Time to tolerance: approximately 1 to 19 months
- Multiple attempts often needed
The real challenge: safety
Adverse events are not rare, they’re defining:
- Allergic reactions: from 0 to 100 percent
- Nephrotic syndrome: from 0 to 33 percent
These complications are far more common than in hemophilia A.
This is the key issue:
- No standardized definition of ‘success.’
- No uniform ITI protocol
- Small, heterogeneous cohorts
We’re comparing apples to oranges across studies.
Clinical insight
- ITI can still work, even after failure or allergic reactions
- But nephrotic syndrome is a major red flag (often treatment-limiting)
- Immunosuppression is widely used but doesn’t eliminate risk
Big picture
Unlike hemophilia A, where ITI is established: Hemophilia B remains a high-risk, low-predictability space
And until we standardize protocols: We’re optimizing therapy without a common playbook.”
Title: Treatment outcomes, safety, and characteristics of immune tolerance induction in patients with hemophilia B and inhibitors: a systematic review
Authors: Shaoyu Yin, Jiahong Wu, Wen Yang, Hongli Mu, Yuexing Peng, Haoran Lu, Rong Li, Hui Bi, Zeping Zhou
Read the Full Article on Research and Practice in Thrombosis and Haemostasis

See more in the gallery.
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 24, 2026, 15:45Kalyan Roy: Platelet Satellitism – An Important Laboratory Artifact
-
Mar 24, 2026, 15:36Doaa EL Demerdash: Call for Hematologists to Support an International ITP Survey
-
Mar 24, 2026, 15:12Simon Senanu: White Blood Cell Differential Count in Clinical Interpretation
-
Mar 24, 2026, 03:17Kathaleen Schnur: Aging with Hemophilia Through a Psychosocial Lens at THSNA 2026
-
Mar 24, 2026, 02:58Pierre Sabouret: The Additive Value of CV Imaging in CVR Assessment
-
Mar 24, 2026, 02:55Shiny K Kajal: FFP as a Targeted Coagulation Therapy
-
Mar 24, 2026, 02:53Ney Carter Borges: Circadian Disruption and Melatonin Deficiency as Cardiovascular Risk Factors
-
Mar 24, 2026, 02:52Hamid Noori: Blood Transfusion Types at a Glance
-
Mar 24, 2026, 02:50Jay Herath: Fitusiran Advancing Hemophilia Care Beyond Factor Replacement